Glypican-3 (GPC-3) has also been tested to modify chimeric antigen receptor (CAR)-T-cells to treat HCC (NCT02715362, NCT03198546, and NCT02905188) administered through the hepatic artery, systemically, or by local injections. The gene discussed is GPC3; the disease is hepatocellular carcinoma.